| Mycosis Fungoides

Rayos vs Adcetris

Side-by-side clinical, coverage, and cost comparison for mycosis fungoides.

Deep comparison between: Rayos vs Adcetris with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsAdcetris has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Adcetris but not Rayos, including UnitedHealthcare

Category

Rayos

Adcetris

At A Glance

RouteOral

FrequencyDaily

ClassCorticosteroid

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassCD30-directed antibody-drug conjugate

Indications

Dermatitis, Atopic
Allergic rhinitis (disorder)
Serum Sickness
Dermatitis Herpetiformis
Contact Dermatitis
Exfoliative dermatitis
Mycosis Fungoides
Pemphigus
Erythema Multiforme
Congenital Adrenal Hyperplasia
Hypercalcemia
thyroiditis; nonsuppurative
Adrenal gland hypofunction
Crohn Disease
Ulcerative Colitis
Autoimmune hemolytic anemia
Anemia, Diamond-Blackfan
Immune thrombocytopenic purpura
Pure Red-Cell Aplasia
Acute leukemia
Lymphoma, Non-Hodgkin
Multiple Sclerosis
Cerebral Edema
Ophthalmia, Sympathetic
Uveitis
Chronic Obstructive Airway Disease
Aspergillosis, Allergic Bronchopulmonary
Aspiration pneumonitis
Asthma
Tuberculosis
Extrinsic allergic alveolitis
Bronchiolitis Obliterans Organizing Pneumonia
Idiopathic eosinophilic pneumonitis
Idiopathic Pulmonary Fibrosis
Pneumonia, Lipid
Sarcoidosis
Nephrotic Syndrome
Primary gout
Ankylosing spondylitis
Dermatomyositis
Polymyalgia Rheumatica
Arthritis, Psoriatic
Polychondritis, Relapsing
Rheumatoid Arthritis
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Vasculitis
Trichinellosis
Tuberculosis, Meningeal

Hodgkin Disease
Angioimmunoblastic Lymphadenopathy
Peripheral T-Cell Lymphoma
Mycosis Fungoides
Diffuse Large B-Cell Lymphoma

Dosing

All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.

Hodgkin Disease (previously untreated Stage III/IV, adults) 1.2 mg/kg (max 120 mg) IV in combination with chemotherapy every 2 weeks for a maximum of 12 doses.

Hodgkin Disease (previously untreated high risk, pediatric) 1.8 mg/kg (max 180 mg) IV in combination with chemotherapy every 3 weeks for a maximum of 5 doses.

Hodgkin Disease (post-auto-HSCT consolidation) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.

Hodgkin Disease (relapsed) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.

Peripheral T-Cell Lymphoma, Angioimmunoblastic Lymphadenopathy (previously untreated) 1.8 mg/kg (max 180 mg) IV in combination with cyclophosphamide, doxorubicin, and prednisone every 3 weeks for 6 to 8 doses.

Peripheral T-Cell Lymphoma (relapsed systemic ALCL) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.

Mycosis Fungoides (relapsed pcALCL or CD30-expressing) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.

Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.2 mg/kg (max 120 mg) IV in combination with lenalidomide and a rituximab product every 3 weeks until disease progression or unacceptable toxicity.

Contraindications

Known hypersensitivity to prednisone or any excipient

Concomitant use with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)

Drug Interactions

1287View drug interactions

782View drug interactions

Adverse Reactions

Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain

Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure

Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone

Most common (>=20%) Peripheral neuropathy, fatigue, nausea, diarrhea, musculoskeletal pain, pyrexia, rash, upper respiratory tract infection, constipation, alopecia

Serious Febrile neutropenia, pneumonia, hepatotoxicity, peripheral motor neuropathy, pulmonary toxicity, progressive multifocal leukoencephalopathy, tumor lysis syndrome, serious and opportunistic infections

Postmarketing Febrile neutropenia, acute pancreatitis, gastrointestinal complications, hepatotoxicity, progressive multifocal leukoencephalopathy, serious and opportunistic infections, hyperglycemia, noninfectious pulmonary toxicity including pneumonitis and ARDS, toxic epidermal necrolysis

Pharmacology

Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.

Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of a chimeric IgG1 anti-CD30 antibody linked to MMAE, a microtubule-disrupting agent; upon binding to CD30-expressing tumor cells the ADC is internalized and MMAE is released via proteolytic cleavage, disrupting the microtubule network within the cell and inducing cell cycle arrest and apoptosis.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Rayos